Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in Allergic Fungal Rhinosinusitis (AFRS)
NCT05545072Phase 3Terminated
- Sponsor
- Emory University
- Start
- Oct 2023
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dupilumab in allergic fungal rhinosinusitis (AFRS), sponsored by Emory University. Primary endpoints: Modified Lund-Kennedy (mLK) Score at Week 52 and Incidence of Oral/Topical Corticosteroid Utilization Per Participant at Week 52. Started Oct 2023; status: terminated.
02
Drugs
03
Conditions
allergic fungal rhinosinusitis (AFRS)
Beyond the preview
Go deeper on NCT05545072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05545072.